Risk-adapted prostate-specific antigen screening guidelines

Risk-adapted prostate-specific antigen screening guidelines has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Feb 28, 2026: “A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population”.

Intervention

1 paper studies it3 findingsUpdated

See all 1 papers on risk-adapted prostate-specific antigen screening guidelines

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“PSA screening following encounters increased from 18.7 to 33.0 per 100 patients (Δ = 14.3; 95% CI, 12.4-16.1) with odds ratio = 2.43 (95% CI, 2.17-2.71)”
A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk populationCancer2026doi:10.1002/cncr.70340

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Human trial1

Studies in people

1 study gave risk-adapted prostate-specific antigen screening guidelines to people and measured what changed.

What changedDesignPeopleSource

up: Increases prostate-specific antigen screening18.7 to 33.0 per 100 patients, OR 2.43 (95% CI, 2.17-2.71)

up: Increases prostate biopsy incidence0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75)

up: Increases prostate cancer2.7-fold (0.25 to 0.68 per 100, p = .007)

Trial15-month4,252 peopleMenage 35 and overMidlife adults; Older adults; primary care encounters in clinics serving Chicago communities with high PCa mortality and Black population densityCancer, Feb 28, 2026

What did studies of risk-adapted prostate-specific antigen screening guidelines find?

3

Studies of risk-adapted prostate-specific antigen screening guidelines measured 3 outcomes: prostate cancer, prostate biopsy incidence and prostate-specific antigen screening.

Prostate cancer

upin humans1

1 study
  1. Risk-adapted prostate-specific antigen screening guidelines increase prostate cancer in humans (primary care encounters) (2.7-fold (0.25 to 0.68 per 100, p = .007)).

    “Total PCa incidence rose 2.7-fold (0.25 to 0.68 per 100, p = .007), with incidence of cancer beyond grade group 1 increasing 3-fold (p = .008).”

    Human trialprimary care encounters15-monthmalesn = 4,252

    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population

    Cancer

More on Prostate cancer

Prostate biopsy incidence

upin humans1

1 study
  1. Risk-adapted prostate-specific antigen screening guidelines increase prostate biopsy incidence in humans (primary care encounters) (0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75)).

    “Biopsy incidence increased from 0.57 to 0.92 per 100 (Δ = 0.35; 95% CI, -0.03 to 0.75), with PCa prevalence at biopsy increasing from 43% to 74%.”

    Human trialprimary care encounters15-monthmalesn = 4,252

    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population

    Cancer

Prostate-specific antigen screening

upin humans1OR 2.43

1 study
  1. Risk-adapted prostate-specific antigen screening guidelines increase prostate-specific antigen screening in humans (18.7 to 33.0 per 100 patients, OR 2.43 (95% CI, 2.17-2.71)).

    “PSA screening following encounters increased from 18.7 to 33.0 per 100 patients (Δ = 14.3; 95% CI, 12.4-16.1) with odds ratio = 2.43 (95% CI, 2.17-2.71)”

    Human trialprimary care encounters in clinics serving Chicago communities with high PCa mortality and Black population density15-monthmalesn = 4,252

    A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population

    Cancer

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months